tiprankstipranks
Shanghai Henlius Biotech, Inc. Class H (HK:2696)
:2696
Hong Kong Market
2696
Shanghai Henlius Biotech, Inc. Class H
RESEARCH TOOLSreports
Want to see HK:2696 full AI Analyst Report?

Shanghai Henlius Biotech, Inc. Class H (2696) Stock News & Sentiment

7 Followers
Henlius Shareholders Unanimously Approve 2025 Reports and Profit Distribution
Premium
Company Announcements
Henlius Shareholders Unanimously Approve 2025 Reports and Profit Distribution
1d ago
2696
Henlius Wins Australian Nod for First-in-Class Bispecific Cancer ADC Trial
Premium
Company Announcements
Henlius Wins Australian Nod for First-in-Class Bispecific Cancer ADC Trial
7d ago
2696
Henlius Starts First-in-Human Trial of Novel KAT6A/B Inhibitor HLX97 in Advanced Tumours
Premium
Company Announcements
Henlius Starts First-in-Human Trial of Novel KAT6A/B Inhibitor HLX97 in Advanced Tumours
7d ago
2696
Henlius Wins EU Approval for Two New Serplulimab Cancer Uses
Premium
Company Announcements
Henlius Wins EU Approval for Two New Serplulimab Cancer Uses
10d ago
2696
Henlius Wins FDA Nod to Begin U.S. Trial of Cetuximab Biosimilar HLX05-N
Premium
Company Announcements
Henlius Wins FDA Nod to Begin U.S. Trial of Cetuximab Biosimilar HLX05-N
10d ago
2696
Henlius Wins Japan Go-Ahead for Global Phase 2/3 Trial of Lung Cancer ADC HLX43
Premium
Company Announcements
Henlius Wins Japan Go-Ahead for Global Phase 2/3 Trial of Lung Cancer ADC HLX43
16d ago
2696
Henlius Starts First-in-Human Trial of Novel Tetra-Specific Cancer Antibody HLX3901
Premium
Company Announcements
Henlius Starts First-in-Human Trial of Novel Tetra-Specific Cancer Antibody HLX3901
20d ago
2696
More HK:2696 News >

2696 News on the Web

Henlius Grants New Share Options and RSUs to Align Incentives With Performance
TipRanks News
Bullish
Henlius Wins NMPA Nod to Start Trials of Cetuximab Biosimilar HLX05-N
TipRanks News
Bullish
Henlius Starts Phase 1 Trial of HLX319, a Subcutaneous Pertuzumab-Trastuzumab Biosimilar in China
TipRanks News
Bullish
Citic Securities Reaffirms Their Buy Rating on Shanghai Henlius Biotech, Inc. Class H (2696)
TipRanks News
Bullish
Henlius Wins China Nod to Expand Indications for Rituximab Biosimilar HANLIKANG
TipRanks News
Bullish
Henlius Wins NMPA Nod to Begin Trials of HER2 Breast Cancer Biosimilar HLX319
TipRanks News
Bullish
Henlius Wins NMPA Nod to Start Trials of Novel Hyaluronidase Injection
TipRanks News
Bullish
Henlius Wins Key EMA Backing for Cancer Drug Serplulimab in Europe
TipRanks News
Bullish

News Score - Last 7 Days

Not enough data to generate a sentiment score
HK:2696
Sector Average
Media Buzz
This Week1 articles
Weekly Average2.75 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is HK:2696’s Media Buzz Sentiment?
1 articles about HK:2696 were published this week. In an average week, 2.75 articles are published.
    What is HK:2696’s weekly average amount of articles?
    In an average week, 2.75 articles about HK:2696 are published.
      What is HK:2696’s News Sentiment?
      Currently, no data Available
      Healthcare Stocks that are Trending in the News
      DOCSDoximity
      AVAHAveanna Healthcare Holdings
      GOSSGossamer Bio
      CGENCompugen
      RLAYRelay Therapeutics
      Showing the stocks with the most bullish news sentiment over the past week